Why the study?
Aortic stenosis causes major morbidity, mortality, and health-care costs, but effective medical therapies to treat or prevent disease development or progression are lacking.
How do modern multimodality imaging techniques assist in the management and assessment of aortic stenosis and bioprosthetic valve degeneration?
How do modern multimodality imaging techniques assist in the management and assessment of aortic stenosis and bioprosthetic valve degeneration?
Multimodality imaging, including echocardiography, CT, MRI, and PET/CT, provides a comprehensive assessment of aortic stenosis severity, progression, and myocardial health to guide patient management and therapeutic development.
Supports multimodality imaging for aortic stenosis assessment; leaves open prospective outcome trials before practice change.
Aortic stenosis is a common condition associated with major morbidity, mortality, and health-care costs. Nevertheless, we currently lack any effective medical therapies that can treat or prevent disease development or progression. Modern advances in echocardiography and CT have helped improve the assessment of aortic stenosis severity and monitoring of disease progression, whereas cardiac MRI informs on myocardial health and the development of fibrosis. In a series of recent studies, ¹⁸F-NaF PET/CT has been shown to assess valvular disease activity and progression, providing mechanistic insights that can inform potential novel therapeutic approaches. This review will examine the latest advances in the imaging of aortic stenosis and bioprosthetic valve degeneration and explore how these techniques can assist patient management and potentially accelerate novel therapeutic developments.
No takes yet. Share an insight, caveat, or question.
Tzolos et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: